Zeox.Pk
ZEOX.PK operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
Business. ZEOX.PK operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-08-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ZEOX.PK operates in the pharmaceuticals industry, focusing on the development and commercialization of biotechnology-based products and therapies.
ZEOX.PK exhibits a highly leveraged capital structure, with total liabilities of $2.95 billion and total equity of -$1.42 billion, resulting in a negative debt-to-equity ratio of -0.25. The company's liquidity position is weak, as evidenced by a current ratio of 0.33, indicating that current assets are insufficient to cover current liabilities. Operating cash flow is negative at -$718 million, and free cash flow is -$5.47 billion, signaling significant cash outflows and limited ability to fund operations or debt obligations.
Profitability metrics are mixed. Gross profit of $4.27 billion suggests strong cost control in production, but this is offset by an operating loss of -$5.39 billion and a net loss of -$5.52 billion. Return on equity is positive at 3.88, but return on assets is negative at -3.62, indicating that the company is not generating returns sufficient to cover the cost of its assets. These figures fall below the industry median for profitability and return metrics, suggesting underperformance relative to peers.
ZEOX.PK's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another. The absence of segment or geographic breakdown in the financial data further complicates the assessment of risk and growth potential.
The company's growth trajectory is uncertain. With a net loss of -$5.52 billion and negative free cash flow of -$5.47 billion, ZEOX.PK is not currently generating the cash flow necessary to sustain operations or fund expansion. There is no disclosed revenue growth in the most recent period, and no forward-looking guidance is available to assess future performance. The lack of capital expenditure ($23 million) suggests limited investment in growth initiatives.
Risk factors include a weak liquidity position, with negative net cash after subtracting total debt, and a high probability of continued operating losses. The company's dilution risk is currently low, as shares outstanding have not changed between basic and diluted counts. However, the negative equity position and high debt levels could necessitate future equity or debt financing, which may lead to dilution or increased financial risk.
Recent events include the filing of financial statements that highlight the company's significant operating losses and negative cash flows. No recent earnings call transcripts or press releases have been disclosed that provide additional insight into the company's strategic direction or operational performance.
- ZEOX.PK is operating at a significant net loss and has negative free cash flow, indicating a lack of financial sustainability.
- The company's return on assets is negative, suggesting poor asset utilization and underperformance relative to industry standards.
- ZEOX.PK's capital structure is highly leveraged, with total liabilities exceeding total assets and a negative equity position.
- The company lacks geographic and segment diversification, increasing its exposure to market-specific risks.
- Liquidity is a critical concern, with a current ratio of 0.33 and negative operating cash flow.
- No recent strategic or operational developments have been disclosed that suggest a path to profitability or growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ZEOX.PK Market data — financials · 2026-05-30
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2026-01-31 vs 2025-01-31): -12.0%Derived (calculated)
- Debt-to-equity (FY 2026-01-31): -7.71xDerived (calculated)
- Current ratio (FY 2026-01-31): 0.70xDerived (calculated)
- Shareholders' equity (YoY) (2026-01-31 vs 2025-01-31): 78.8%Derived (calculated)
- Total assets (YoY) (2026-01-31 vs 2025-01-31): 65.9%Derived (calculated)
- Current assets (annual): USD 2.01MSEC XBRL filing
- Total liabilities (annual): USD 2.95MSEC XBRL filing
- Shares outstanding (annual): 7.61MSEC XBRL filing
- Total assets (annual): USD 2.57MSEC XBRL filing
- Current liabilities (annual): USD 2.89MSEC XBRL filing
- Shareholders' equity (annual): USD -383KSEC XBRL filing
- Cost of revenue (YoY) (2025-10-31 vs 2024-10-31): 10.3%Derived (calculated)
- Net income (YoY) (2025-10-31 vs 2024-10-31): -17.3%Derived (calculated)
- Gross margin (FY 2025-10-31): 82.1%Derived (calculated)
- Gross profit (YoY) (2025-10-31 vs 2024-10-31): 13.0%Derived (calculated)
- Capex (YoY) (2025-10-31 vs 2023-10-31): -11.5%Derived (calculated)
- R&D expense (YoY) (2025-10-31 vs 2024-10-31): -39.0%Derived (calculated)
- Operating income (YoY) (2025-10-31 vs 2024-10-31): -1.3%Derived (calculated)
- Operating cash flow (YoY) (2025-10-31 vs 2024-10-31): 50.5%Derived (calculated)
- Net margin (FY 2025-10-31): -106.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-10-31 vs 2024-10-31): -16.2%Derived (calculated)
- EPS (basic) (YoY) (2025-10-31 vs 2024-10-31): -16.2%Derived (calculated)
- Revenue (YoY) (2025-10-31 vs 2024-10-31): 12.5%Derived (calculated)
- Operating income (annual): USD -5.39MSEC XBRL filing